Evolution of Translational PK/PD: A Pharma
Lisa Benincosa, PhD ’93
March 7, 2017
190 Kapoor Hall, UB South Campus
Lisa Benincosa, PhD ’93, is vice president and global head of drug metabolism and pharmacokinetics and bioanalytical research and development for Roche Pharmaceutical Research and Early Development in Basel, Switzerland. She also serves as deputy head of pharmaceutical sciences.
In 1992, Benincosa joined the clinical pharmacokinetic department at SmithKline Beecham Pharmaceuticals, later taking on additional global responsibility for preclinical and clinical pharmacokinetics/pharmacodynamics (PK/PD) focusing on infectious disease, respiratory and metabolic diseases.
She joined Pfizer in 2001, directing clinical PK/PD, and became executive director and Groton/New London Clinical Pharmacology site head in 2003. She joined Roche in 2009.
During her career, Benincosa has contributed to preclinical and clinical regulatory filings across therapeutic areas, and has presented at national scientific meetings. She has received numerous awards, including the Pfizer People Leader Award in 2007, a Tribute to Women and Industry Award in 2012 and a Leadership Excellence Award from Roche Pharma Research and Early Development in 2016. Benincosa earned a BS in pharmacy in 1987 from the West Virginia University School of Pharmacy, which named her to its inaugural Hall of Fame.
A member of the UB School of Pharmacy and Pharmaceutical
Sciences Dean’s Advisory Council, Benincosa also serves on
the leadership council for the Center for Pharmacometrics and
Systems Pharmacology, University of Florida College of Pharmacy,
and is a longtime member of the American Association of
Pharmaceutical Scientists and the American Society for Clinical
Pharmacology and Therapeutics.
The David Chu Lectureship was established at UB in 2011 through the generosity of David and Jane Chu.
C.K. David Chu, PhD, is a Distinguished Research Professor, Emeritus, of Pharmaceutical and Biomedical Sciences at the College of Pharmacy, University of Georgia. He obtained his PhD in Medicinal Chemistry from the University at Buffalo in 1975 under the mentorship of Professor Thomas Bardos.
Dr. Chu has published over 300 drug discovery related scientific papers and over 50 US patents have been awarded to him. Several of his invented compounds are undergoing clinical trials in the therapeutic areas of cancer, hepatitis B virus, HIV and shingles. An elected member of American Association of Advancement of Science, Dr. Chu received a MERIT Award from the NIH in 2001, and the UGA Inventor of the Year Award in 2002.
He will receive the University at Buffalo School of Pharmacy and
Pharmaceutical Sciences' most distinguished recognition, the Willis
G. Gregory Alumni Award, in April 2017.